Full-Time

Vice President Endocrinology Clinical Research

Clinical Research Endocrinology

Crinetics Pharmaceuticals

Crinetics Pharmaceuticals

501-1,000 employees

Clinical-stage pharma developing rare endocrine therapies

Compensation Overview

$346k - $433k/yr

+ Discretionary Annual Target Bonus + Stock Options + ESPP + 401k Match

Remote in USA

Remote

Category
Biology & Biotech (1)
Required Skills
biometrics
biostatistics
Google Cloud Platform
Requirements
  • MD degree with at least 13 years clinical research experience within a biopharmaceutical company and a minimum of 12 years in a supervisory/leadership role
  • Board certification in internal medicine, or related specialty
  • Broad understanding and practice of endocrinology- and hands on experience working in clinical pharmacology/translational medicine/early development capacity is required
  • Experience in interacting with the FDA and/or EU regulatory agencies
  • Previous successful regulatory authorization experience strongly preferred
  • Demonstrated expertise and experience in translational medicine, in close collaboration with discovery, toxicology, biomarkers and clinical pharmacology
  • Strong general knowledge of Good Clinical Practice, International Council for Harmonisation guidelines and regulatory requirements that apply to clinical drug development
  • Intimate knowledge of and high-level expertise in the day-to-day medical monitoring of clinical trials and relationships with Biostatistics, Data Management, and Medical Writing
  • Excellent leadership skills and ability to function effectively in a fast-paced, high accountability environment
  • Ability to build and lead a strong team with ability to manage, mentor, and develop team
  • Strong project planning, negotiation, and presentation skills and ability to contribute creative yet practical solutions
  • Ability to work independently and collaboratively, prioritizing tasks efficiently and meeting clinical and corporate timelines
  • Strategic thinker, team leader and individual contributor capable of working in a high growth, dynamic, science-driven environment
  • Able to prioritize and parallel process multiple workstreams, comfortable changing gears, and making definitive decisions
  • Self-starter who enjoys rolling up their sleeves and digging into the details; rigorous attention to details and data, while not losing sight of the bigger picture
  • Able to conceive and execute innovative approaches to clinical development
  • Ability to inspire and earn respect of the leadership team, Board members, the investment community, colleagues, and staff
  • Well-developed presentation and written communication skills; effective at Board level, as well as with the scientific/medical community, advisers, and colleagues
  • Ethical, with the highest standards of integrity, recognizing that we are the creators of hope for our patients and the health care professionals who serve them as well as stewards of the investments of all our shareholders.
Responsibilities
  • Serve as deputy for CMO on as need basis
  • Plays a key role in the design and implementation of the clinical development strategy across the entire endocrinology portfolio
  • Leads creation and implementation of innovative trial designs to accelerate delivery of high-quality data to address key scientific questions, including proof-of-concept
  • Provide clinical leadership and lead clinical communication to upper management on trial issues, patient recruitment, investigator’s feedback, patient enrollment issues and present a plan of action for resolution of issue
  • Author and/or review clinical documents required for the conduct of clinical studies, including clinical protocols (and amendments), informed consent documents, investigator brochures, and safety management plans in compliance with regulations and good clinical practices
  • Contribute to/lead clinical strategies for successful development of Crinetics endocrine related drug candidates, ensuring alignment with corporate goals and regulatory requirements
  • Serve as the Clinical Research expert to the conception and regular refinement of Target Product Profiles (TPP)
  • Oversee or lead the creation and implementation of a Clinical Development Plan (CDP) for each indication being pursued, using the TPP as a guidance; including coordinating cross-functional collaborations with other departments as needed throughout the asset life cycle; ensure that scenarios and Go/No Go are incorporated into the CDPs
  • Serve as clinical subject matter expert in discussions with external experts and regulatory authorities
  • Engage with Discovery team provide input on selection of future targets
  • In collaboration with other departments (Biometrics, Clinical Operations, Pharmacovigilance) lead the conception, medical monitoring and medical interpretation of Crinetics endocrinology clinical trials
  • Develop strong external relationships with investigators, research sites, patient advocacy groups and KOLs to design clinical trials that answer important medical questions
  • Contribute to the development of relevant sections of clinical and regulatory documents such as amendments to protocols, briefing books, safety updates, responses to Health Authorities questions and collaborates with Regulatory Affairs in the preparation of regulatory interactions
  • Support/lead the preparation, drafting and finalization of all the clinical sections of all endocrine related products NDA and MAA while incorporating the clinicians’ perspective. Lead the timely drafting of clinical responses to questions from regulatory authorities
  • Lead ongoing data review, analysis, and interpretation to understand safety and efficacy profile of the investigational drugs
  • Support business development in identification of new targets and assessment of commercial opportunities
  • Develop and manage departmental budgets that effectively achieve desired goals that are balanced with the financial objectives of the broader clinical research organization
  • Other duties as assigned
Desired Qualifications
  • Specialty training in adult or pediatric endocrinology
  • Previous regulatory authorization experience
Crinetics Pharmaceuticals

Crinetics Pharmaceuticals

View

Crinetics Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare endocrine diseases and endocrine-related tumors. Its work centers on creating novel orally administered treatments, with CRN00808 for acromegaly currently in Phase 2 trials. The product approach involves identifying targets in endocrine pathways (often GPCRs), and engineering oral drug candidates that modulate these targets to treat conditions with few existing options. The company differentiates itself by concentrating on rare endocrine disorders and advancing candidates through clinical development, aiming to secure regulatory approvals and then pursue commercialization, often via partnerships or licensing with larger pharma players. Its goal is to provide effective, targeted therapies for patients with unmet endocrine needs and to bring approved medicines to market through disciplined clinical development and external collaborations.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • PALSONIFY's early U.S. launch shows over 125 prescribers and 200 patient starts.
  • European approval opens launches in Germany and Austria, expanding near-term revenue potential.
  • Atumelnant entering phase II/III adds a second late-stage catalyst beyond PALSONIFY.

What critics are saying

  • PALSONIFY's launch remains small, with about 5% uptake and reimbursement friction.
  • Crinetics depends heavily on one commercial product, so setbacks would hit revenue immediately.
  • Jeff Knight's April 2026 departure adds execution risk during commercialization and pipeline scaling.

What makes Crinetics Pharmaceuticals unique

  • PALSONIFY is the first once-daily oral acromegaly therapy approved in the EU and U.S.
  • Crinetics specializes in GPCR-targeted small molecules for rare endocrine diseases and tumors.
  • Its pipeline spans 10+ disclosed programs, including atumelnant and CRN09682.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Crinetics Pharmaceuticals who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Holidays

Unlimited Paid Time Off

PTO/vacation

Holiday/Vacation not?

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

2%
Yahoo Finance
Mar 28th, 2026
Crinetics director sells $181K in shares under pre-scheduled trading plan

Crinetics Pharmaceuticals director Rogerio Vivaldi Coelho sold 5,000 shares of common stock on 12 March 2026, valued at approximately $181,000, according to an SEC Form 4 filing. The sale was executed under a Rule 10b5-1 trading plan adopted on 11 December 2025. The transaction reduced Coelho's direct holdings by 23.47%, from 21,300 to 16,300 shares, worth approximately $595,000. Shares were sold at a weighted average price of $36.15, close to the market price of $36.51 on the transaction date. This marks Coelho's only disclosed open-market sale for the clinical-stage biotechnology company, which develops oral therapeutics for rare endocrine diseases. Crinetics had a market capitalisation of $3.97 billion as of 12 March 2026.

Stock Titan
Mar 23rd, 2026
Crinetics (NASDAQ: CRNX) coo-level executive Jeff Knight to resign by April 10, 2026.

Crinetics (NASDAQ: CRNX) coo-level executive Jeff Knight to resign by April 10, 2026. Filing Impact Filing Sentiment Rhea-AI Filing summary. Crinetics Pharmaceuticals announced that Jeff Knight has decided to resign as Chief Development and Operating Officer, effective on or about April 10, 2026. The company states that he is leaving to pursue another opportunity and that his resignation is not due to any disagreement over operations, policies, or practices. Crinetics plans to reassign all of Mr. Knight's managerial responsibilities and direct reports to other members of its executive leadership team, signaling a redistribution of his duties rather than the creation of a new replacement role at this time. Insights. Senior operating executive departs; duties redistributed internally. The departure of the Chief Development and Operating Officer at Crinetics Pharmaceuticals is notable because it affects leadership over development and operations. The company clarifies he is leaving to pursue another opportunity and explicitly notes no disagreements over corporate matters. All of his responsibilities will shift to other executive leaders, indicating an internal reallocation rather than an immediate external hire. The long-term impact will depend on how smoothly this transition proceeds and whether future disclosures outline any organizational or strategic changes following his exit effective on or about April 10, 2026. 03/23/2026 - 09:04 AM Faq. Why did Jeff Knight resign from Crinetics Pharmaceuticals (CRNX)? Jeff Knight resigned as Chief Development and Operating Officer to pursue another opportunity. The company states his resignation is not related to any disagreement regarding operations, policies, or practices, suggesting a voluntary career move rather than a dispute-driven departure. When will Jeff Knight's resignation from Crinetics Pharmaceuticals (CRNX) become effective? Jeff Knight's resignation as Chief Development and Operating Officer is effective on or about April 10, 2026. Until then, he remains in his role while the company prepares to reassign his responsibilities to other members of its executive leadership team. Did Jeff Knight have any disagreements with Crinetics Pharmaceuticals (CRNX) before resigning? Crinetics Pharmaceuticals states that Jeff Knight's resignation is not related to any disagreement with the company. This includes no disputes regarding operations, policies, or practices, indicating the departure is not tied to reported internal conflict or governance issues. How will Crinetics Pharmaceuticals (CRNX) handle Jeff Knight's responsibilities after his resignation? Crinetics plans to reassign all of Jeff Knight's managerial responsibilities and direct reports to other executive leadership team members. This approach redistributes his development and operating duties internally rather than immediately appointing a direct successor or creating a new standalone role. What executive role did Jeff Knight hold at Crinetics Pharmaceuticals (CRNX)? Jeff Knight served as Chief Development and Operating Officer at Crinetics Pharmaceuticals. This combined role covered leadership over drug development and operational functions, which the company now intends to redistribute among other executives following his effective resignation date in April 2026. Does the resignation announcement for CRNX mention any changes to company strategy? The announcement focuses on Jeff Knight's resignation and the reassignment of his responsibilities. It does not outline specific strategic changes, instead emphasizing that duties will move to other executive leaders and that the departure is not due to disagreements over company operations or policies. Filing exhibits & attachments. 3 documents

Yahoo Finance
Mar 9th, 2026
Crinetics' acromegaly drug PALSONIFY hits $5.4M in Q1 sales, EU approval due in May

Crinetics Pharmaceuticals reported early commercial success for PALSONIFY (paltusotine), its acromegaly treatment, with $5.4 million in first-quarter revenue and over 200 patient starts. The drug, priced at $290,000 annually, has attracted 125-plus unique prescribers across academic and community settings. The company received a positive CHMP recommendation for paltusotine in Europe, with approval expected around May. CFO Tobin Schilke said Crinetics is well funded into 2030 following recent capital raising. The pipeline focuses on novel small-molecule GPCR therapies, including atumelnant advancing to Phase 3 for congenital adrenal hyperplasia and paltusotine entering Phase 3 for carcinoid syndrome. On reimbursement, over half of patients secured coverage through medical exceptions, whilst others receive temporary support through a Quick Start programme.

Yahoo Finance
Feb 27th, 2026
Crinetics Q4 revenue hits $6.2M as PALSONIFY gains 125+ prescribers, atumelnant enters phase II/III trial

Crinetics Pharmaceuticals reported Q4 revenue of $6.2 million, including $5.4 million from PALSONIFY, its first commercial product launched in the US. The company has seen early adoption with over 125 unique prescribers and more than 200 enrollment forms, whilst several major payers have added the drug to formularies with label-aligned prior authorisation. The company announced atumelnant, the first ACTH receptor antagonist tested in humans, will enter a global phase II/III trial in the first half of 2025 for ACTH-dependent Cushing's syndrome. Crinetics used $326.2 million cash in 2025 and, following a January 2026 offering, has approximately $1.4 billion in cash and investments. Management provided 2026 GAAP operating expense guidance of $600–650 million, with funds expected to support operations into 2030.

MarketScreener
Jan 7th, 2026
Crinetics Pharmaceuticals prices $350M public offering to fund PALSONIFY launch

Crinetics Pharmaceuticals has priced an underwritten public offering of 7.62 million shares of common stock at $45.95 per share, expecting to raise approximately $350 million in gross proceeds. The company has also granted underwriters a 30-day option to purchase up to an additional 1.14 million shares. The San Diego-based pharmaceutical company, which focuses on treatments for endocrine diseases and endocrine-related tumours, plans to use the net proceeds to fund commercial activities for its recently approved drug PALSONIFY™, research and development of product candidates, and general corporate purposes. The offering is expected to close on 8 January 2026. Leerink Partners, J.P. Morgan, Evercore ISI, Piper Sandler and Cantor are acting as joint bookrunning managers for the offering.